GlassScriptPhysician profile
Holly Navid
NPI 1407228257
$1,114.43
in general payments reported to CMS, 2019-2025
13 companies · $219 in 2025
The $219 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $101 · 2021: $166 · 2022: $208 · 2023: $193 · 2024: $228 · 2025: $219.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $639.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $639.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $329.39 | 2021-2022 | |
| Alcon Vision LLC | $196.33 | 2023-2024 | Total30, Precision 1 |
| Bausch & Lomb Americas INC. | $106.50 | 2022-2025 | Infuse, Scoutpro Osmolarity System, Lotemax Sm |
| Optovue, INC. | $101.41 | 2019 | |
| Johnson & Johnson Vision Care, INC. | $99.75 | 2024-2025 | |
| Astellas Pharma US INC | $66.74 | 2024-2025 | Izervay |
| Tarsus Pharmaceuticals, INC. | $42.05 | 2024-2025 | Xdemvy |
| Oyster Point Pharma, INC. | $37.99 | 2023 | Tyrvaya |
| Harrow Eye, LLC | $36.39 | 2025 | Vevye |
| Dompe US, INC. | $33.52 | 2025 | Oxervate |
| Abbvie INC. | $24.74 | 2023 | |
| Coopervision INC. | $23.61 | 2022 | |
| Sun Pharmaceutical Industries INC. | $16.01 | 2023 | Cequa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Holly Navid listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.